Investigator-Initiated Research

We measure ourselves by the impact we have on people with cancer.
Let’s continue
to innovate.

SpringWorks is committed to supporting Investigator-Initiated Research (IIR) to advance medical and scientific knowledge relating to its product candidates and current therapeutic areas of interest.

Let’s learn together.

SpringWorks will consider unsolicited research proposals submitted electronically† by external investigators interested in studying SpringWorks products or product candidates in therapeutic areas of interest.

SpringWorks will consider research proposals for clinical, preclinical, and non-interventional/observational studies as part of this program.

SpringWorks receives many requests for research support. Research support decisions are based on a careful evaluation of the scientific rigor of the research proposal, the expertise and experience of the investigator, the feasibility of supporting the research and the strategic interest of SpringWorks.

Interested investigators may submit research proposals in our strategic areas of interest, which we list below, for
review by SpringWorks:

 Preclinical Phase 1 Phase 2 Phase 3 Regulatory Submission Approved Collaborators

Nirogacestat

• Desmoid tumor      -Combination treatment (excluding radiation)      -Adjuvant or neoadjuvant approach      -Treatment duration      -Pathogenesis and management of adverse events      -Drug holiday/rechallenge      -Symptomatic desmoid tumor without radiologic progression       • Non-desmoid tumor      - Monotherapy and rational combinations with other therapies in solid tumors

Mirdametinib

• Neurofibromatosis type 1 (NF1) plexiform neurofibroma (PN)      -Neoadjuvant/adjuvant therapy      -Combination therapies for NF1-PN      -PN-related morbidity prevention      -PN growth and treatment-related biomarkers      -Spinal PNs      -Efficacy following prior MEKi therapy failure and MEKi sequencing      -Mechanism of resistance • Other NF1 manifestations      -Combination therapies for malignant peripheral nerve sheath tumors -Skeletal manifestations -Neurocognitive deficits -Pain control • Targeted oncology (mirdametinib and brimarafenib preclinical proposals only) - NF1-mutant tumor agnostic - Combination therapy in gynecologic cancers • Other tumor types      - Combination therapies for high grade glioma - Combination therapies for low grade glioma - RASopathies - Combination therapies for sarcoma - NF2-associated and sporadic schwannoma - TSC1 and TSC2 associated tumors - Combination therapies for acute myeloid leukemia with overactive MAPK signaling

Pre-Clinical In Progress:

Nirogacestat

Pre-Clinical In Progress:

• Desmoid tumor      -Combination treatment (excluding radiation)      -Adjuvant or neoadjuvant approach      -Treatment duration      -Pathogenesis and management of adverse events      -Drug holiday/rechallenge      -Symptomatic desmoid tumor without radiologic progression       • Non-desmoid tumor      - Monotherapy and rational combinations with other therapies in solid tumors

Mirdametinib

Pre-Clinical In Progress:

• Neurofibromatosis type 1 (NF1) plexiform neurofibroma (PN)      -Neoadjuvant/adjuvant therapy      -Combination therapies for NF1-PN      -PN-related morbidity prevention      -PN growth and treatment-related biomarkers      -Spinal PNs      -Efficacy following prior MEKi therapy failure and MEKi sequencing      -Mechanism of resistance • Other NF1 manifestations      -Combination therapies for malignant peripheral nerve sheath tumors -Skeletal manifestations -Neurocognitive deficits -Pain control • Targeted oncology (mirdametinib and brimarafenib preclinical proposals only) - NF1-mutant tumor agnostic - Combination therapy in gynecologic cancers • Other tumor types      - Combination therapies for high grade glioma - Combination therapies for low grade glioma - RASopathies - Combination therapies for sarcoma - NF2-associated and sporadic schwannoma - TSC1 and TSC2 associated tumors - Combination therapies for acute myeloid leukemia with overactive MAPK signaling

†SpringWorks shall have no obligation to maintain the confidentiality of submitted research proposals and documents. This statement shall not supersede or otherwise affect the terms of any existing agreements between SpringWorks and the institution/investigator on whose behalf a research proposal is being submitted.

Review process

All proposals will be reviewed by SpringWorks’ IIR Program Committee, which is comprised of a cross-functional team.

If approved, the IIR Program typically provides a research grant in the manner of funding and/or supply of study drug or materials. SpringWorks provides no guarantees that it will provide support for submitted proposals. The terms under which SpringWorks will provide support will be set forth in a written agreement.

The IIR Program Committee routinely meets to review IIR proposals. Proposals will be accepted on a rolling basis with no defined submission deadlines. Incomplete submissions may cause a delay in the Committee’s review and response.

Submission guidelines

Please complete the form below with as much information as possible (including uploading any additional documents you wish SpringWorks to receive with your proposal).

Fields marked with an asterisk (*) are preferred fields of information.  If you do not wish to use the form below, you may submit a concept proposal by using the “upload” feature at the bottom of this page and clicking “Submit”.